From the Journals

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

Share

In a nationwide cohort study in Taiwan, sodium-glucose cotransporter-2 inhibitors were linked to reduced risks of kidney, cardiovascular, and hepatic complications in patients with type 2 diabetes and cirrhosis over a median follow-up of 2.3 years. The study analyzed data from 24,259 patients, revealing that those treated with these inhibitors had a significantly lower incidence of end-stage kidney disease, acute kidney injury, major cardiovascular events, and hepatic decompensation compared to those on dipeptidyl peptidase-4 inhibitors. However, limitations including the lack of laboratory data on cirrhosis severity were noted.

Original Source(s)

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

  • by Henry Thomas

  • March 10, 2026

Related Content

Sleep Duration Signals Metabolic Change

Weekend sleep recovery shows mixed metabolic associations depending on weekday sleep duration.

Empagliflozin Tested in Real-World Data

Investigators assess whether EMPA-REG findings extend to broader patients with type 2 diabetes.

The Oral GLP‑1 Era Has Arrived 

And chromatographers are about to be very busy…